Insider Transactions in Q2 2021 at Selecta Biosciences Inc (SELB)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 02
2021
|
Carsten Brunn President and CEO |
SELL
Open market or private sale
|
Direct |
4,806
-2.11%
|
$19,224
$4.38 P/Share
|
|
Jun 01
2021
|
Carsten Brunn President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,938
+4.58%
|
-
|
|
May 26
2021
|
Peter G Traber Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
20,000
+12.86%
|
$60,000
$3.99 P/Share
|
|
May 26
2021
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
926,170
+4.61%
|
$3,704,680
$4.0 P/Share
|
|
May 25
2021
|
Peter G Traber Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+4.15%
|
$15,000
$3.48 P/Share
|
|
May 25
2021
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
383,830
+2.06%
|
$1,151,490
$3.55 P/Share
|
|
May 24
2021
|
Peter G Traber Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
12,500
+10.16%
|
$37,500
$3.32 P/Share
|
|
May 24
2021
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
590,000
+3.2%
|
$1,770,000
$3.38 P/Share
|
|
May 21
2021
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Indirect |
2,773,479
+13.85%
|
$8,320,437
$3.19 P/Share
|
|
May 07
2021
|
Takashi Kei Kishimoto Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,629
+7.12%
|
$27,258
$2.77 P/Share
|